Gilead enters $2B immuno-oncology deal with Arcus Biosciences
Under the 10-year deal, Gilead will have the right to option product candidates from Arcus' pipeline, with the companies sharing responsibility for development and commercialization.
Under the 10-year deal, Gilead will have the right to option product candidates from Arcus' pipeline, with the companies sharing responsibility for development and commercialization.
New research by the Cancer Research Institute puts the number of industry-wide combination trials at 1,105.